Amar Maletira
Analyst · William Blair. Your line is open
Thank you, Bill. Fiscal Q3 Viavi revenue of $196 million met the guidance midpoint. OSP revenue exceeded the guidance range due to better than expected demand in our anti-counterfeiting business, while NSE revenue was below the guidance range. Viavi revenue declined 11.1% year-over-year, as the growth in the OSP business was offset by the decline in NSE. Viavi’s operating income at $23.4 million declined 10.7% year-over-year. Operating margin of 11.9% was near the guidance midpoint and flat from the prior year despite lower revenue in fiscal Q3. Overall, Viavi's operating expenses declined 10.6% year-over-year or $11.7 million, driven by expense reductions across the board. EPS at $0.09 exceeded our guidance range of $0.06 to $0.08. The upside to the high end of our guidance range of $0.08 was due to some non-operational benefits. Now, moving to our fiscal third quarter 2017 results by business segment. Starting with NSE. NSE revenue at $132.1 million declined 16.6% year-over-year, driven by a 16% decline in the NE segment, and an 18.5% decline in the SE segment. NSE gross margins at 64.5% increased 100 basis points year-over-year. This was due to 540 basis points of improvement in SE's gross margins at 61.7%, partially offset by a modest decline of 30 basis points in NE's gross margins at 65.3%. NSE operating expense in the quarter was $89.6 million. Despite a 10.9% reduction in NSEs operating expenses from a year ago, we still reported a 3.3% operating loss due to the steep decline in NSE revenue. During the quarter, we executed a previously announced NSE restructuring plan. In Q3 we reduced approximately 6% of our work force, primarily in the SE business segment. The balance of the 10% work force reduction or the remaining 4% will largely occur in our fiscal Q4 or the June quarter. We're currently ahead of schedule to deliver the targeted annualized net OpEx savings of $35 million. Beyond the stated restructuring plan, we also have additional levers to reduce NSE expenses. The total aggregate charges for this restructuring plan, a majority of which is related to severance is approximately $25 million year-to-date with the balance of up to $5 million to be incurred through the rest of the calendar year 2017. NSE achieved a book to bill ratio above one. Turning to OSP; revenue of $63.9 million increased 2.9% from year-ago levels, driven by an better than expected recovery in our anti-counterfeiting business. Gross margin at 57.4% declined 40 basis points due to product mix. Operating margin of 43.5% improved by 110 basis points from last year, reflecting good management of operating expenses. Now moving to the balance sheet. Our total cash and short-term investments ending balance was approximately $1.45 billion, with total net cash of 345 million. Operating cash flow for the quarter was $17.3 million. During fiscal Q3 we sold 1.3 million Lumentum shares for a net proceed of $62.1 million, with an average selling price of $48.80 per share. Our book cost basis of these shares is approximately $8.57 per share. As a result, we realized on a GAAP only P&L, an accounting gain of approximately $51.2 million. As of the last day of fiscal Q3, we have remaining 0.4 million shares of Lumentum valued at $20.8 million. We repurchased a total of 5.2 million shares of Viavi stock during the quarter at a cost basis of $9.91 per share, including commissions for a total of $51.9 million. Of the $150 million share buyback program to-date, we have repurchased shares worth approximately $96 million. We will continue to be opportunistic in monetizing our remaining Lumentum position and repurchasing our Viavi stock. In March, we completed our $460 million senior convertible note offering, which included our initial purchases exercising the overallotment option of 60 million. These notes have a 1% interest rate, a conversion price of $13.22 per share, and will mature in march 2024, unless earlier converted or repurchased. Viavi received $451.2 million in net proceeds. We intend to use these net proceeds together with cash on hand for opportunistically refinancing our outstanding 0.6% to 5% senior convertible notes due 2033, as well as for general corporate purposes. Now on to our guidance. We expect fiscal fourth quarter 2017 revenue for Viavi to be in the range of $188 million to $204 million, operating margin at 13% plus or minus 1%, and EPS to be $0.07 to $0.09. We expect NSE revenue to be at $137 million, plus or minus $6 million with operating margin at 1% plus or minus 1%. We expect OSP revenue to be at $59 million, plus or minus $2 million with operating margin at 41% plus or minus 1%. There was no meaningful 3D sensing revenue in fiscal Q3 and we do not expect it in the current fiscal fourth quarter. While we are seeing the expected recovery in OSP's core revenue in second half fiscal 2017, the anti-counterfeiting demand remains cyclical. Our tax expense is expected to be approximately $5 million. We expect other income and expenses to reflect a net expense of approximately $1.5 million and our share count to be approximately 235 million shares. With that I'll turn the call to Oleg.